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Abstract
Nuclear Autoantigen of 14 kDa (NA14) was originally identified using the serum of a Sjögren’s
syndrome (SS) patient as probe in screening a human testis cDNA expression library. To date there
is no report in the systematic analysis of the prevalence of autoantibodies to NA14. In this study,
anti-NA14 was determined in several rheumatic diseases from independent cohorts in the US and
Japan. The prevalence of anti-NA14 were 18/132 (13.6%) in primary SS, 0/50 (0%) secondary SS,
2/100 (2%) SLE, 1/43 (2.3%) scleroderma, 0/54 (0%) rheumatoid arthritis, 1/29 (3.4%) polymyositis/
dermatomyositis, and 0/58 (0%) normal healthy controls. The frequencies of anti-NA14 positive sera
in primary SS are statistically greater than normal healthy controls (p=0.006), secondary SS
(p=0.044), and other rheumatic diseases. Furthermore, among 11 anti-NA14 positive primary SS
sera, 4/11 (36.3%) sera were negative for both anti-SS-A/Ro and SS-B/La antibodies. Thus anti-
NA14 autoantibodies may be useful for the discrimination of primary versus secondary SS and serve
as a diagnostic marker for primary SS especially in seronegative (anti-SS-A/Ro and anti-SS-B/La
antibodies negative) patients with SS.
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2. INTRODUCTION
Sjögren’s syndrome (SS) is a member of the family of systemic autoimmune diseases, in which
the immune response is activated to recognize a limited subset of ubiquitously expressed self
antigens (1,2). Although SS is characterized primarily by chronic sialadenitis and
dacryoadenitis, a variety of systemic manifestations have been described. The disease may be
isolated (primary SS) or it may occur in association with other rheumatic diseases (secondary
SS) such as rheumatoid arthritis (RA), scleroderma (SSc), and systemic lupus erythematosus
(SLE). Although the pathogenesis of SS remains unclear, one of the central clues comes from
the observation that the immune system in SS targets a restricted and highly specific group of
intracellular autoantigens (3). These cellular antigens that are often targeted by high-titer
autoantibody response are a diverse group of macromolecules that are ubiquitously expressed.
In systemic autoimmune diseases, many of these cellular antigens are components of protein-
nucleic acid complexes but otherwise share no obvious features in terms of subcellular
distribution, protein structure, or function (4). In spite of the diversity of self antigens, the
specificity of the autoimmune response is remarkably predictive of disease phenotype, such
that specific autoantibodies have become useful in clinical diagnosis and prognosis (5–8). The
predominant autoantigen targets in SS are the ribonucleoprotein autoantigens SS-A/Ro and
SS-B/La (9). There have been many reports of other less prevalent autoantibodies such as
coiled-coil-rich proteins including nuclear mitotic apparatus protein (NuMA) (10,11),
members of golgin family (12), alpha-fodrin (13) and M3 muscarinic receptors (14,15). Other
autoantigens described in SS include poly (ADP) ribose polymerase (PARP) (16), 90-KDa
nucleolar organizer region protein (NOR90) (17), p80-coilin (18), and many others that do not
appear to be restricted to SS. Although autoantibodies to SS-A/Ro and SS-B/La are indicative
of SS, their presence is not specific since they are found with some frequency in patients with
other systemic autoimmune diseases such as SLE (5,9).
Nuclear autoantigen 14 kDa (NA14) was originally identified as a novel autoantigen
recognized by an autoimmune serum from a patient with SS (19). Ramos-Morales et al reported
that neither the autoimmune serum nor a polyclonal antibodies raised against recombinant
NA14 recognized endogenous NA14 by conventional IIF using HeLa cells (19). For this
reason, subcellular localization was achieved by expression of an HA-tagged version of NA14.
Under these conditions, transfected NA14 localized to the nucleus and thus NA14 was reported
as a nuclear autoantigen (19). Although physiological role of NA14 remains unknown so far,
several reports recently have suggested NA14 protein localizes at not only nucleus but also
centrosomes and play an important role in cell division and proliferation (20–22). Although
expression of NA14 in salivary and lacrimal glands has not been determined, it is reasonable
to expect that it is expressed in these tissues since NA14 seems to be widely expressed.
NA14 was identified as an autoantigen recognized by a human SS serum. However, there is
no report regarding the prevalence of autoantibodies to NA14 in systemic autoimmune diseases
to date and correlation with clinical manifestation is completely absent. In this study, anti-
NA14 autoantibodies were determined in patients with various rheumatic diseases from cohorts
in both US and Japan.
3. MATERIALS AND METHODS
3.1. Human sera
Human rheumatic diseases sera were obtained from laboratory serum bank of Juntendo
University Hospital and the University of Florida Autoimmune Disease Center with
institutional ethics approval. Patient sera with primary SS (1′SS, n=132), secondary SS (2′SS,
n=50), SLE (n=100), RA (n=54), SSc (n=43), PM/DM (n=29) and normal healthy controls
(NHS, n=58) were assessed. Patients with SS fulfilled the American–European Consensus
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Criteria (23). Patients with RA, SLE, and SSc fulfilled the criteria of American College of
Rheumatology (24–26). Patients with PM/DM fulfilled the Bohan’s criteria (27). Patients sera
with secondary SS was derived from patients with SS in association with other rheumatic
diseases, including SLE (n=27), RA (n=15), PM/DM (n=3), SSc (n=2), primary APS (n=2),
and polyarteritis nodosa (PN, n=1).
3.2. Recombinant NA14 protein
NA14 full length cDNA were cloned into pET28 expression vector and introduced into
Escherichia coli BL21 (DE3; Novagen, Madison, WI, USA) as previously described (28). The
expression construct was confirmed by direct DNA sequencing in both strands. Bacterial
pellets were suspended in 6M guanidium hydrochloride containing buffer, and the recombinant
proteins were purified by nickel column chromatography according to manufacturer’s
instructions (Qiagen, Valencia, CA, USA). The concentration of the purified recombinant
protein was measured by a Protein DC Kit (Bio-Rad, Hercules, CA, USA) and the samples
were stored at −80°C.
3.3. Enzyme-linked immunosorbent assay
The ELISA protocol described by Rubin (29) was used with some modifications. In brief,
nickel column affinity purified recombinant protein was diluted in phosphate-buffered saline
to a final concentration of 1μg/ml and then coated on Immunolon2 microtiter plates (Dynatech
Laboratories, Alexandria, VA, USA) overnight at 4°C. Human sera were diluted at 1:1000 and
then incubated in the antigen-coated wells. Horseradish peroxidase-conjugated goat anti human
IgG (CALTAG Laboratories, San Francisco, CA, USA) was used at 1:5000 dilution and the
substrate 2,2′-azinobis (3-ethylbenzthiazoline) sulfonic acid was added as the detection
reagent. Samples were analyzed in duplicate and the average optical density (OD) at 405 nm
with a substrate development of 15 min was used for data analysis. The cut off value designating
a positive reaction was the mean OD of normal healthy controls +5 standard deviation (SD).
In some anti-NA14 antibody positive sera with primary SS, antibodies to SS-A/Ro and SS-B/
La were measured by ELISA system (MASCAP test) according to manufacturer’s instructions
(MBL, Tokyo, Japan). Statistical analysis was performed by Chi-square test.
3.4. Immunoblotting
Affinity purified recombinant proteins were loaded on 15% SDS-PAGE gels (1μg/lane),
separated by electrophoresis, and transferred to nitrocellulose membranes using a Semi-Dry
Tran-Blot apparatus (Bio-Rad) as described previously (28,30). Human sera containing anti-
NA14 antibodies were used at dilutions of 1:100. Detection of bound antibodies was achieved
using horseradish peroxidase-conjugated goat anti-human IgG antibody (CALTAG), used at
1:5000 dilution, and developed with Supersignal enhanced chemiluminescence (Pierce
Products, Rockford, IL, USA).
4. RESULTS
As NA14 was originally reported as autoantigen recognized by patient sera with SS, we
initiated investigation in the prevalence of autoantibodies to NA14 using affinity purified
recombinant protein in ELISA format. To avoid experimental deviation caused by individual
center study, ELISA was independently performed using the same protocol at Juntendo
University and the University of Florida testing patients sera with various rheumatic diseases
including primary SS, secondary SS, SLE, SSc, RA, PM/DM, and normal healthy controls.
Figure 1 shows independent data derived from Japan (upper panel) and USA (lower panel)
respectively. The combined prevalence of anti-NA14 were 18/132 (13.6%) primary SS, 0/50
(0%) secondary SS, 2/100 (2%) SLE, 1/43 (2.3%) SSc, 0/54 RA (0%), and 1/29 (3.4%) PM/
DM. As expected, anti-NA14 antibody positive sera were observed most frequently in primary
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SS. Interestingly, none of the secondary SS patients had autoantibodies to NA14. There were
no obvious differences observed between patient cohorts in Japan and USA. Although a few
anti-NA14 positive sera were observed in other rheumatic diseases like SLE, SSc, and PM/
DM, anti-NA14 autoantibodies were almost exclusively observed in only primary SS compared
to other rheumatic diseases.
To compare the prevalence of anti-NA14 autoantibodies in primary SS to those of other
rheumatic diseases more precisely, we combined Japanese and USA data and performed further
statistical analysis (Table 1). Although p value was not significant comparing to PM/DM due
to small number of the sera, the prevalence of anti-NA14 autoantibodies in primary SS was
statistically greater than in other rheumatic diseases and normal healthy controls. Interestingly,
none of sera from patients with secondary SS reacted with NA14 and the frequency of anti-
NA14 positive sera in primary SS are statistically greater than normal healthy controls
(p=0.002) and secondary SS (p=0.0041) and other rheumatic diseases. The reactivity against
NA14 recombinant protein in primary SS was also confirmed by immunoblotting (Figure 2).
To investigate the clinical association between primary SS and anti-NA14 autoantibodies
further, we measured anti-SS-A/Ro and SS-B/La antibodies in anti-NA14 positive sera with
primary SS. Among 11 available anti-NA14 positive sera, 4/11 (36.3%) sera were negative for
both anti-SS-A/Ro and SS-B/La antibodies (Table 2). These data suggest anti-NA14 antibodies
not only can discriminate primary and secondary SS serologically, but also it can be used as a
potential diagnostic marker for primary SS even in the case when both anti-SS-A/Ro and SS-
B/La antibodies are negative.
5. DISCUSSION
5.1. Diseases specificity of anti NA-14 antibodies
In our current study, anti-NA14 autoantibodies were observed primarily in primary SS
compared to other rheumatic diseases including secondary SS. Our data showed anti-NA14
antibodies appeared independent of anti-SS-A/Ro anti-SS-B/La antibodies and 36.4% (4/11)
of anti-NA14 positive sera was negative for anti-SS-A/Ro and anti-SS-B/La antibodies. It has
been proposed that primary SS negative for anti-SS-A/Ro and SS-B/La antibodies represent
immunologically distinct populations compared to anti-SS-A/Ro and SS-B/La antibodies
positive population. Kelly et al. reported that the presence of anti-SS-A/Ro antibodies
identified patients with more severe systemic diseases (31). Subsequently, Davidson et al.
described that parotid swelling and lymphadenopathy were more common in anti-SS-A/Ro
and SS-B/La antibodies positive patients and the risk of developing non-Hodgkin’s lymphoma
was higher in this group compared to anti SS-A/Ro and SS-B/La antibodies seronegative
patients (32). Therefore, primary SS may be divided into clinically distinct groups based on
the presence of specific autoantibodies such as anti-SS-A/Ro antibodies. Although we have
not been able to analyze the characteristics of anti-NA14 antibodies positive patients due to
the lack of clinical information, the detection of anti-NA14 antibodies may provide useful
information with primary SS and future studies will be needed to examine correlations with
clinical activities.
5.2. Coiled-coil proteins elicit autoantibodies production
The unique characteristic of NA14 is that it is predicted to contain coiled-coil secondary
structure in the N-terminal half. This is interesting since we and others reported a class of
coiled-coil proteins that are recognized as intracellular autoantigens in systemic autoimmune
diseases (12,33). Coiled-coil rich autoantigens have been noted in several cytoplasmic
organelles, including a family of Golgi complex antigens known as golgins (12,33), endosomal
proteins EEA1 (34) and CLIP-170 (35), centrosomal proteins pericentrin (36), ninein (37), and
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Cep250 and Cep110 (38). The mitotic organelles are also known to be associated with coiled-
coil rich autoantigens, including NuMA (10,11,39), and centromere associated protein CENP-
E (38,40,41) and CENP-F (42,43). It is not clear why coiled-coil rich protein can selectively
elicit autoimmune response; however, one possible explanation is that this protein structure
may be more stable and can promote the induction and production of antibodies in certain
diseases states such as SS. It is important to note that the immune response is not merely directed
at crossreactive coiled-coil structure, because the human autoimmune response to coiled-coil
proteins appears to be highly specific in our study (28,30).
5.3. Pathogenesis of NA14 in primary SS
Although it has been reported that NA14 play an important role for cell division and
proliferation (20–22), the exact physiological roles of NA14 remain unknown. Recently, Aki
T et al reported that the orphan receptor Transmembrane Protein Regulated in Adipocytes of
40kDa (TPRA40/GPR175) could bind to NA14 and TPRA40 regulated cell division in mouse
embryocytes through the interaction with NA14 (44). TPRA40 was originally cloned and its
level found to be significantly increased in diabetic mice (45). Recently, a full-length cDNA
encoding a human seven transmembrane domain orphan receptor (GenBank accession number
AB037108) was isolated from human fetal brain. The deduced amino acid sequence shows
85.8% homology to rat TPRA40 and 83.3% homology to mouse TPRA40 (46). The regulation
of cell division by TPRA40 was also observed in human HeLa cells (44). Although the report
showed the interaction of TPRA40 and NA14 can regulate cell division, the precise mechanism
of interaction of NA14 and TPRA40 has not been elucidated (44). TPRA40 is considered to
be a membrane receptor, therefore, its ligand should exist in soluble form like chemokines or
as cell surface membrane protein which can function in promoting cell-cell interaction. Since
NA14 is found to be an intracellular protein to date, it is surprising that NA14 interacts with
the cell surface TPRA40. One wild speculation is that NA14, being a relatively short
polypeptide, may exist not only as an intracellular protein but also a secreted protein like
chemokines. As it was reported that NA14 is widely expressed in variety of tissues, NA14 may
be overexpressed in the salivary and lacrimal glands tissues in primary SS and this may induce
autoantibody production by an antigen-driven mechanism described in SS (47). It is also
possible that NA14 has chemokine-like activity and play a role in lymphocytes infiltration in
salivary and lacrimal tissues in primary SS patients and the infiltration leads the tissue
destruction. If NA14 is overexpressed in salivary and lacrimal tissues in primary SS, it might
serve as a chemokine and attract lymphocytes from blood vessel to the tissues. We are now
conducting experiments to examine the expression of NA14 in salivary tissues with primary
SS patients and assay NA14 for chemokine-like activities.
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Figure 1.
Serum antibodies to NA14 in rheumatic disease cohorts from Juntendo University (Japan) and
University of Florida (USA). ELISA using recombinant NA14 antigens were used and the cut
off value designating a positive reaction was the mean OD (405 nm) of normal healthy controls
+5 standard deviations. The preferential positive reaction was observed in sera from primary
SS (1′SS). Statistical analysis was performed by Chi-square test.
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Figure 2.
Confirmation of ELISA positive sera with Western blot against recombinant NA14 protein.
The results of two representative SS sera and two normal human sera each are shown.
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Table 2
Correlation of SS-A/Ro and SS-B/La reactivity in anti-NA14 positive sera
Anti-SS-A/Ro Anti-SS-B/La n percent
+ + 3 28%
+ − 4 36%
− + 0 0%
− − 4 36%
11 100%
11 anti-NA14 positive sera from 1′SS were analyzed for reactivity against SS-A/Ro and SS-B/La
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